» Articles » PMID: 39456957

P57 Phosphorylation Modulates Its Localization, Stability, and Interactions

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Oct 26
PMID 39456957
Authors
Affiliations
Soon will be listed here.
Abstract

p57 is a member of the cyclin-dependent kinase (CDK) Interacting Protein/Kinase Inhibitory Protein (CIP/Kip) family that also includes p21 and p27. Different from its siblings, few data are available about the p57 protein, especially in humans. Structurally, p57 is an intrinsically unstructured protein, a characteristic that confers functional flexibility with multiple transient interactions influencing the metabolism and roles of the protein. Being an IUP, its localization, stability, and binding to functional partners might be strongly modulated by post-translational modifications, especially phosphorylation. In this work, we investigated by two-dimensional analysis the phosphorylation pattern of p57 in different cellular models, revealing how the human protein appears to be extensively phosphorylated, compared to p21 and p27. We further observed clear differences in the phosphoisoforms distributed in the cytosolic and nuclear compartments in asynchronous and synchronized cells. Particularly, the unmodified form is detectable only in the nucleus, while the more acidic forms are present in the cytoplasm. Most importantly, we found that the phosphorylation state of p57 influences the binding with some p57 partners, such as CDKs, LIMK1 and CRM1. Thus, it is necessary to completely identify the phosphorylated residues of the protein to fully unravel the roles of this CIP/Kip protein, which are still partially identified.

References
1.
Arboleda V, Lee H, Parnaik R, Fleming A, Banerjee A, Ferraz-de-Souza B . Mutations in the PCNA-binding domain of CDKN1C cause IMAGe syndrome. Nat Genet. 2012; 44(7):788-92. PMC: 3386373. DOI: 10.1038/ng.2275. View

2.
Kullmann M, Pegka F, Ploner C, Hengst L . Stimulation of c-Jun/AP-1-Activity by the Cell Cycle Inhibitor p57. Front Cell Dev Biol. 2021; 9:664609. PMC: 8076676. DOI: 10.3389/fcell.2021.664609. View

3.
Watanabe H, Pan Z, Schreiber-Agus N, DePinho R, Hurwitz J, Xiong Y . Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 1998; 95(4):1392-7. PMC: 19016. DOI: 10.1073/pnas.95.4.1392. View

4.
Kavanagh E, Joseph B . The hallmarks of CDKN1C (p57, KIP2) in cancer. Biochim Biophys Acta. 2011; 1816(1):50-6. DOI: 10.1016/j.bbcan.2011.03.002. View

5.
Lee M, Reynisdottir I, Massague J . Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 1995; 9(6):639-49. DOI: 10.1101/gad.9.6.639. View